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There is a lack of data related to activity uptake and particle track distribution in targeted alpha therapy. These data are required
to estimate the absorbed dose on a cellular level as alpha particles have a limited range and traverse only a few cells. Tracking
of individual alpha particles is possible using the Timepix semiconductor radiation detector. We investigated the feasibility of
imaging alpha particle emissions in tumour sections from mice treated with Thorium-227 (using APOMAB), with and without
prior chemotherapy and Timepix detector. Additionally, the sensitivity of the Timepix detector to monitor variations in tumour
uptake based on the necrotic tissue volume was also studied. Compartmental analysis model was used, based on the obtained
imaging data, to assess the Th-227 uptake. Results show that alpha particle, photon, electron, and muon tracks were detected and
resolved by Timepix detector. The current study demonstrated that individual alpha particle emissions, resulting from targeted
alpha therapy, can be visualised and quantified using Timepix detector. Furthermore, the variations in the uptake based on the
tumour necrotic volume have been observed with four times higher uptake for tumours pretreated with chemotherapy than for
those without chemotherapy.
1. Introduction
The relationship between the characteristics of a particular
radiation type and its impact on irradiated biological tissues
and cells plays an important role in estimating the efficacy and
applicability of targeted radiotherapies [1]. In a specific case of
targeted alpha therapy (TAT), a tumour-specific antibody or
protein is radiolabelled with an alpha-emitting radionuclide,
termed a radioimmunoconjugate [2, 3]. This radioimmuno-
conjugate attaches preferentially to tumour-specific antigens
that can be expressed on a tumour cell membrane and release
high-linear energy transfer (LET) alpha particles with kinetic
energy of a few MeV. The traversal of these short-ranged
alpha particles through target and neighbouring tumour cells
results in localised radiation damage and ultimately cell death
[2, 4]. TATcan, however, also result in so-called cross fire irra-
diation in which antigen-negative nontumour cells in close
vicinity of the radioimmunoconjugate are also irradiated and
damaged.Themagnitude of this radiation damage (to tumour
or healthy cells) strongly depends on the tumour-specific
uptake of the particular radioimmunoconjugate.
To date, there is a lack of methods that can quantify
alpha particle emissions in biological systems. One of the
few devices presently available (known as the “𝛼-camera”)
combines autoradiography with a scintillation detector and
optical registration using a charge-coupled device. In the
study of Ba¨ck and Jacobsson, the distribution of At-211
labelled antibody and antibody fragments in human tumour,
mouse kidney, and whole-body sections were examined
[6]. The 𝛼-camera had a resolution of 35 ± 11 𝜇m, and
Hindawi Publishing Corporation
Computational and Mathematical Methods in Medicine
Volume 2015, Article ID 612580, 7 pages
http://dx.doi.org/10.1155/2015/612580
2 Computational and Mathematical Methods in Medicine
Pixelated 300𝜇m thick Si
detector chip (256 × 256
pixels, 55𝜇m pitch)
14mm
Detector bias Read-out ASIC
chip Timepixvoltage (∼100V)
Figure 1: Timepix detector structure, courtesy of [5].
the quantitative analysis proved that the pixel intensity has
a linear relationship with the activity of the imaged tissue.
The results demonstrated the ability of the 𝛼-camera to be
employed in small-scale dosimetry for TAT as it was able
to provide quantitative data on a microscopic scale [6].
Furthermore, the 𝛼-camera was also used to examine the
accumulation of an At-211 radioimmunoconjugate admin-
istered to mice with ovarian cancer micrometastases. The
activity level and the number of tumour cell clusters were
determined by imaging one section with the 𝛼-camera and
by staining a consecutive section with hematoxylin and eosin
[7]. The study demonstrated that the radioimmunoconjugate
had high uptake and retention at the tumour surface and that
dose estimates to micrometastases could be calculated using
the 𝛼-camera.
Timepix is a new prototype radiation detector which
takes advantage of recent developments of the complemen-
tary metal-oxide-semiconductor (CMOS) technology for
constructing integrated circuits. Timepix consists of a silicon
semiconductor layer, divided into an array of pixels, which is
bumped-bonded to an electronics integrated layer (Figure 1).
Each pixel is connected to an individual charge-sensitive
preamplifier, a discriminator and a counter [8, 9], and a 4-
bit digital-to-analogue converter (DAC) to adjust the voltage
threshold (4-bit DAC for threshold adjustment) [10].
Timepix is a sophisticated microdosimeter that can be
used for a wide range of experiments with photons, electrons,
and other charged particles and has applications in fields such
as space physics, nuclear physics, radiotherapy physics, imag-
ing, and radiation protection. One of its main advantages is
that it can measure energy deposition directly and in real
time [11]. For example, in the work of Esposito et al., Timepix
was used to trace 𝛽-particles froma C-14 sample [12, 13]. C-14
was deposited on a low-density paper foil, evaporated before
packing in 10 𝜇m thick Mylar, and being read by the detector
[12].The image was analysed in terms of clusters of hit pixels,
which gave an indication of the interaction position of the
𝛽 particle with the detector. The result showed that Timepix
was highly sensitive with a minimum detectable activity of
0.0077 Bq and with a spatial resolution of 76.9 𝜇m at full
width at half maximum (FWHM) [13].
In this paper, we present the first results for using
Timepix to visualise TAT ex vivo in mouse tumour sections.
As mentioned above, the 𝛼-emitting radioimmunoconjugate
binds to its cancer-specific antigen. The emitted 𝛼 particles
deposit their kinetic energy inside a target cell, as well as
in surrounding cells, potentially resulting in cell death. In
the current work, the DAB4 murine monoclonal antibody
(trademarked as APOMAB), which binds to necrotic tumour
cells [14, 15], was used and was radiolabelled with Thorium-
227 as described in [4]. Since there is a spatial correlation
inside a tumour between the necrotic and the hypoxic regions
[4], we hypothesised that targeting or binding of DAB4 to
necrotic tumour regions would result in nearby hypoxic
tumour cells receiving cross dose and hence undergoing
radiation-induced death. Hypoxic tumour cells are generally
resistant to low LET radiation like that of X-rays, which is
typically employed in clinical radiation therapy. Furthermore,
by increasing the number of dead tumour cell targets, for
example, after chemotherapy, the tumour uptake of the
radioimmunoconjugate would be increased, consequently
increasing the tumour dose [16]. In order to confirm this
hypothesis, qualitative and quantitative detection and anal-
ysis of the radioimmunoconjugate uptake and its distribu-
tion within the tumour volume are required, using suitable
microdosimetric detection techniques. In this study, we used
the Timepix microdosimeter to detect radiation emissions
from tumour sections of mice treated with Thorium-227
APOMAB to image and quantify alpha particle emissions at
a micrometre level.
2. Materials and Methods
2.1. Th-227. The radionuclideThorium-227 is an alpha emit-
ter produced from actinium-227 with a half-life of 18.7
days, making it, attractive for use in therapeutic applications
[17, 18]. Alpha particles have a short range of only a few
cell diameters in tissue (<100𝜇m [18]). The higher LET
of alpha particles results in greater biological effectiveness
compared to other radiation types such as X-rays or electrons
[19]. Along with alpha particle emissions, the Th-227 decay
chain also results in the release of 𝛽-particles and a low
percentage of X- and gamma rays prior to reaching a stable
isotope (Lead-207). The Th-227 decay chain and the mean
energies of major particles produced in this decay chain
are presented in Figure 2. Th-227 used in the current work
was purchased through the National Isotope Development
Centre, Department of Energy, USA.
2.2. Preparation of Autoradiography Sample
2.2.1. Monoclonal Antibody Production, Conjugation, and
Radiolabelling with 227Th. The La-specific murine mono-
clonal antibodyDAB4 (APOMAB) [20] in conjugation buffer
(0.1M sodium bicarbonate, 0.1M monosodium phosphate,
and pH 8.5) was mixed with 50-fold molar excess of the
bifunctional chelator p-SCN-Bn-DOTA (Macrocyclics,USA)
and incubated at room temperature for four hours with
rotation. After buffer-transfer to 0.5M sodium acetate buffer
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Figure 2: The decay chain of Th-227, half-lives, and mean energies of emitted particles.
(pH 5), the ratio of DOTA :mAb was determined as previ-
ously described [21] and was approximately 4 : 1.
227Th was purified as previously described [18] imme-
diately prior to radiolabelling. DAB4-p-SCN-DOTA was
incubated overnight with purified Th-227 using an Eppen-
dorf Thermomixer (37∘C, 550 rpm constant). Samples were
washed three times and buffer-transferred to phosphate-
buffered saline (pH 7.4). The activity of the radioimmuno-
conjugate was determined using a Germanium detector and
MCDWIN version 3.08 software (FAST ComTec, Germany),
with the main gamma peaks of 236 and 256 keV (17.6%
and 9.5% abundance, resp.) used to quantify Th-227 activity
and of 269 and 154 keV peaks (13.9% and 5.7% abundance,
resp.) used to quantify Radium-223. The specific activity of
radioimmunoconjugates was 400 kBq/mg, with <1% Ra-223
and <1% unbound Th-227 present, as determined by instant
thin-layer chromatography.
2.2.2. LL2 Tumour Model and Treatment of Tumour-Bearing
Mice. All animal experiments were approved by the SA
Pathology Animal Ethics Committee, Adelaide, and con-
ducted following institutional ethical guidelines. Six- to eight-
week-old female C57Bl/6 mice were injected subcutaneously
in the right flank with 106 LL2 cells (this cell line is derived
from transplantable murine Lewis lung carcinoma). Tumour
size was measured using electronic callipers, and tumour
volume was determined using the following calculation:
tumour volume = (𝑎2×𝑏)/2, where a is the shortest diameter
and b is the longest diameter of the tumour. Treatment
commenced when tumours reached 45–60mm3. To gener-
ate more necrotic tumour cells for Th-227-DAB4 binding,
some mice also received chemotherapy prior to injection
with Th-227-DAB4. These were treated intravenously with
50mg/kg gemcitabine (Hospira, Australia) on days 1 and 2
and 2.5mg/kg cisplatin (Hospira) on day 1. 18 kBq of 227Th-
DAB4 was administered on day 3. Mice were euthanised
2 days after administration of Th-227 labelled antibody via
cervical dislocation, and tumours were collected and fixed
in 10% neutral-buffered formalin. Tumours were paraffin
embedded, and 5 𝜇m sections were cut for imaging.
2.3. Timepix Radiation Detector. The Timepix radiation
detector, used in the current work, was purchased from
Amsterdam Scientific Instruments (ASI), the Netherlands.
The device consists of a silicon chip, 1.408 × 1.408 cm2 in size
containing 256 × 256 pixels, with each pixel having an area of
55 × 55 𝜇m2 and 300 𝜇m depth.
The chip can collect positive or negative charges [9], and
the range of particle energies to be detected can be selected
for a uniform performance using adjustable thresholds. The
device can be operated in one of three main modes to
either count single particles (Medipix mode), measure the
arrival time of events/particles (Timepix mode), or measure
the energy deposited in each pixel for events between the
thresholds (time over threshold (TOT)mode) [10].This offers
the possibility of using the detector for a wide range of
applications for photon and particle detection and energy
spectrometry in addition to imaging and tomography.
TheASITimepix detector is combinedwith the beamdata
acquisition software, SoPhy (Software for Physics), developed
by the provider. The SoPhy software allows one to control
Timepix acquisitionmodes such as selection of the operation
mode, adjustment of suitable energy thresholds, cluster sizes,
and other acquisition settings using multiwindows. The
recorded data and frames/images can be exported to and
processed using other programs such as Matlab or ImageJ.
In the current work, before any measurements and fol-
lowing manufacturer recommended procedure, pixel equal-
isation was performed to ensure a uniform response of
all pixels. Subsequently, tumour sections mounted on glass
microscope slides were placed 2 cm away from the detector
with the front face of the detector uncovered to allow the
emitted alpha particles to penetrate the Timepix silicon chip
(Figure 3). A simple steel collimator with 1 cm radius and
2 cm in length was manufactured in-house and positioned
around the tumour section using epoxy glue. Bias voltage
of 5V was applied to Timepix. The TOT mode was selected
along with alpha particle filter. This acquisition filter allows
identification of individual alpha particles detected (amongst
other detected particles) aswell as determination of the centre
pixel in a charge cluster produced in the Timepix silicon
chip by a traversing alpha particle. The total acquisition time
was approximately 14 hours with 0.01 seconds per frame.
Individual frames as well as the total integrated image can
be evaluated. In the current work, the detected number of
alpha particle hits from individual samples was evaluated and
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Figure 3: Image of the experimental setup. (a) Tumour section with a 2 cm diameter collimator mounted on top of a tumour section. (b) A
tumour section in front of the uncovered Timepix detector.
compared after correction for decay and normalisation for
tumour section size and acquisition time.
2.4. Compartmental Analysis. The compartmental model
[22] was used in the current work to calculate and compare
the radioimmunoconjugate uptake in TAT-treated tumours.
It is assumed that there are threemain compartment volumes:
the blood volume (𝐵), tumour volume (𝑇), and a free
volume (𝐸), where the radioactive source will escape from the
blood. It is assumed that, after injection, the Th-227-DAB4
will distribute throughout all volumes. The blood and the
escape volumes are open volumes where the radiolabelled
immunoconjugate can escape from. The tumour volume,
however, is a closed volume where the taken-up Th-227-
DAB4 concentration will remain steady as shown in Figure 4.
For simplicity, it is assumed in the current work that,
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the blood volume, 𝑑𝐶
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are the so-called transfer (uptake) coeffi-
cients for tumour and for the escape volumes.
Variations in Th-227-DAB4 concentration in tumour
volume, 𝑑𝐶
𝑇
/𝑑𝑡, are due to Th-227 uptake from the blood
volume and due to its depletion through radioactive decay of


































Figure 4: Compartmental model for the autoradiography usingTh-
227 labelled DAB4.
Assuming, for simplicity, that the tumour volume transfer
coefficient, 𝑘
𝑇
, is much higher than escape volume transfer
coefficient, 𝑘
𝐸
































In our case, for tumour sections treated with only Th-227-
DAB4, the concentration of the radioactive material at time 𝑡















Similarly, for tumour sections treated with chemotherapy
prior to Th-227-DAB4 administration, the concentration of
























Figure 5: (a) and (b): images of tumour sections frommice treated with 227Th-DAB4 alone. (c) and (d): images of two tumour sections from
mice treated with chemotherapy followed by 227Th-DAB4. The red circle indicates the approximate tumour section boundaries.
The ratio of radioisotope concentrations between the radio-
























𝑇,nochemo𝑡 (1 − 𝑒−(𝜆−𝑘𝑇,nochemo))
.
(6)
Considering that the decay probability coefficient 𝜆 is much
smaller compared to the transfer coefficient 𝑘
𝑇
, the above














Once the mouse has been euthanised and/or all of the initial
activity has been taken up by the tumour and escape volumes
(e.g., at time 𝑡max), the amount of radioisotope in the tumour







As both tumour sample types (treated and not treated with
chemotherapy) will decay with the same decay probability,
the number of recorded alpha emissions will be directly
proportional to the amount of radioisotope taken up by
the tumour prior to a mouse being euthanatised. As a
result, from the measurement point of view, the number
of alpha hits detected by Timepix detector is proportional
to isotope concentrations, 𝐶
𝑇,chemo and 𝐶𝑇,nochemo, during
measurements. As a result, from the number of recorded
alpha hits measured at different time intervals, the transfer
coefficients for the two scenarios could be determined.
3. Results and Discussion
Figure 5 shows acquired integrated images of sections from
four tumours: two tumours from mice treated with 227Th-
DAB4 alone ((a), (b)) and two tumours from mice treated
with chemotherapy followed by 227Th-DAB4 ((c), (d)). Even
though the collimator was positioned around the tumour
section, the collimator was not touching the detector, leaving
a small (∼2mm) air gap. As a result, particles emitted at
smaller angles, compared to a trajectory perpendicular to the





Figure 6: Timepix responses to electron,Muon, X-/gamma ray, and
alpha particle.
detector, can still reach the detector. These are observed as
hits outside the red circle in Figure 5.
High LET alpha particles release their kinetic energy
in more than one pixel as they pass in the semiconductor
detector, forming a charge cluster.The small dots recorded in
the image represent X- and gamma rays. An electron passage
will result in a wavy and short track, and amuon track will be
detected as a straight, long line (Figure 6).
An automated method using ImageJ was used to deter-
mine the number of alpha particle hits. These were also
counted manually for comparison. The differences between
the two methods varied between 4 and 20 hits. Using the
automatedmethod, the number of hits varied between 93 and
251, for the sections that did not receive chemotherapy, and
between 445 and 582, for the sections that were treated with
chemotherapy before administeringTh-227-DAB4.
As shown in Figure 7, the recorded alpha particle hits
for each sample were corrected for radioactive decay (based
on the time elapsed between the Th-227 administration and
Timepix measurement), the area of each sample, and total
acquisition time, resulting in the alpha particle acquisition
rate between 27.6 and 44.8 hits/cm2⋅hour for tumour sections
of mice not previously given chemotherapy and between 94.0
and 206.8 hits/cm2⋅hour for sections that were treated with
chemotherapy followed by 227Th-DAB4.
Corrected alpha particle acquisition rates were statisti-
cally analysed using one-way ANOVA for their significance,
using GraphPad Prism software, yielding P value of 0.026
(<0.05, two-tailed), confirming that the observed differences
between the two sample groups are significant.
Energy spectra of alpha particles detected from decay of
Th-227 and its daughters were also acquired and an example
is presented in Figure 8 where the lowest and the highest
energies can be determined.The energy varies between 4 and
7.4MeV, corresponding to the expected energy range of alpha
particles produced byTh-227 decay chain.
Using the compartmental analysis, corresponding trans-
fer coefficients for the two samples can be determined when
repeating the measurements for at least one sample type
at different times. The data can be plotted using (4) or (5)
and the transfer coefficient can be estimated. The ratio in

























Chemo drug + Th-227-DAB4
Figure 7: Measured alpha particle hits per unit tumour area per 1
hour for two groups of tumour sections: 4 sections with and 3 sec-

















Figure 8:The detected alpha particle spectrum as emitted fromTh-
227-DAB4 from a single tumour section.
found to be approximately 4. If one of the transfer coefficients
is known from repeatedmeasurements, the second one can be
determined from (7).
4. Conclusion
Tumour sections were imaged in the current work to charac-
terise the pattern of uptake and distribution ofTh-227-DAB4.
High resolution autoradiographs of radiolabelled tumour
sections were acquired, showing alpha particles, 𝛽 particles,
electrons, and X-ray tracks. The Timepix measurements
also showed an increased uptake of Th-227–DAB4 following
chemotherapy due to an increase in necrotic tissue volume.
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The experiment showed that the Timepix detector can be
used effectively for autoradiography in TAT to provide high-
resolution images. Development of a fine collimator can
improve the definition of the tumour boundaries and identify
the geometrical origin of detected alpha particles within
the sample. It was also shown that, in principle, the data
acquired by Timepix can be used for compartmental analysis
to quantify the uptake of radioimmunoconjugate in targeted
alpha therapy.
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